Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
BGT226
Cat. No.:
OB0225LY-0433
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Product Overview
Description:
BGT226 is an orally available small molecule that specifically inhibits the PI3K/AKT signaling pathway with potential anti-tumor activity.
Synonym:
BGT226 free base; NVP-BGT226; 915020-55-2; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-[4-piperazin-1-yl-3-(trifluoromethyl)phenyl]imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 8-(6-Methoxypyridin-3-yl)-3-methyl-1-(4-(piperazin-1-yl)-3-(trifluoromethyl)phenyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one
CAS No.:
915020-55-2
Compound CID:
11978790
Formula:
C28H25F3N6O2
Formula Weight:
534.53
Specification
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
BGT226 can be used for cancer biomarker research or play an important role in anti-cancer drug development.
Library Information
Targets:
PI3K/Akt/mTOR pathway
Receptors:
mTOR; PI3Kα; PI3Kβ; PI3Kγ
Pathways:
Autophagy; PI3K/Akt/mTOR signaling
Plate Number:
AOCL-6
Plate Location:
e10
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10 mM DMSO
DMSO Max Solubility:
65 mg/ml; 121.6 mM
